AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding maintenance for at least 12 months
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding maintenance for at least 24 months
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with breastfeeding maintenance at 6 months
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with breastfeeding maintenance at 12 months
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with breastfeeding maintenance at 24 months
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant not using a pacifier
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal grandmother breastfeeding support
Number of subjects: 228
Study 29855364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 228
Study 28619025 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an additional face-to-face consultation and follow-up telephone call with a 'healthy lifestyle clinician'
Number of subjects: 540
Study 28619025 — intervention group
Group type: COMPARATOR
Intervention: Usual care for chronic disease risks provided in routine consultations
Number of subjects: 540
Study 28619025 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle clinician intervention
Number of subjects: 540
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Core lab interpretation of stress echocardiography
Number of subjects: 81
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress echocardiography
Number of subjects: 81
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic stress echocardiography
Number of subjects: 81
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Good or excellent image quality
Number of subjects: 81
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor or fair image quality
Number of subjects: 81
Study 26683627 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant interpretations in patients with no or mild LV myocardial ischemia
Number of subjects: 81
Study 23246393 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 111
Study 23246393 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 111
Study 23246393 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 21977987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 5244
Study 21977987 — intervention group
Group type: EXPERIMENTAL
Intervention: Top SNP (rs445925)
Number of subjects: 5244
Study 21977987 — intervention group
Group type: EXPERIMENTAL
Intervention: Second top SNP (rs6511720)
Number of subjects: 5244
Study 21977987 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS analysis
Number of subjects: 5244
Study 18280835 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, sc 66 µg/Kg/d
Number of subjects: 25
Study 18280835 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 25
Study 17128839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) vaccination (40 microgram, 2 ml)
Number of subjects: 34
Study 17128839 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) vaccination (10 microgram, 0.5 ml)
Number of subjects: 34
Study 17128839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination (10 microgram, 0.5 ml)
Number of subjects: 34
Study 12957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one vessel disease (VD)
Number of subjects: 101
Study 12957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with two vessel disease (VD)
Number of subjects: 101
Study 12957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with three vessel disease (VD)
Number of subjects: 101
Study 12957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 101
Study 12957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with more diseased vessels
Number of subjects: 101
Study 12957728 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 101
Study 10856529 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol-niacin
Number of subjects: 133
Study 10856529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 9170692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum public health nurse telephone visit
Number of subjects: 0
Study 9170692 — intervention group
Group type: EXPERIMENTAL
Intervention: Clerk call
Number of subjects: 0
Study 9170692 — intervention group
Group type: COMPARATOR
Intervention: Control group (mailed out information package)
Number of subjects: 0
Study 9170692 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone visit
Number of subjects: 0
Study 9170692 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-baby groups attendance
Number of subjects: 0
Study 8228158 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant physicians (n=44)
Number of subjects: 70
Study 8228158 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant physicians (n=5)
Number of subjects: 70
Study 8228158 — intervention group
Group type: COMPARATOR
Intervention: Control physicians (n=21)
Number of subjects: 70
Study 31178989 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) + Virtual Reality (VR)
Number of subjects: 26
Study 31178989 — intervention group
Group type: COMPARATOR
Intervention: Occupational Therapy (OT)
Number of subjects: 26
Study 29380613 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mix‐MP (metronidazole, minocycline, ciprofloxacin)
Number of subjects: 22
Study 29380613 — intervention group
Group type: COMPARATOR
Intervention: 3Mix‐MP‐R (metronidazole, clindamycin, ciprofloxacin)
Number of subjects: 22
Study 29380613 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mix‐MP and 3Mix‐MP‐R
Number of subjects: 22
Study 26111868 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin D
Number of subjects: 50
Study 26111868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26111868 — intervention group
Group type: COMPARATOR
Intervention: Both groups (vitamin D and placebo)
Number of subjects: 50
Study 24597840 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 0.5 mg
Number of subjects: 239
Study 24597840 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg
Number of subjects: 239
Study 24597840 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 5 mg
Number of subjects: 239
Study 24597840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 24597840 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin (all doses)
Number of subjects: 239
Study 24597840 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 239
Study 22386848 — intervention group
Group type: EXPERIMENTAL
Intervention: User Centred Critical Care Discharge Information Pack (UCCDIP)
Number of subjects: 0
Study 22386848 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19049846 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg)
Number of subjects: 100
Study 19049846 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 100
Study 17953640 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-PDT
Number of subjects: 18
Study 17953640 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT
Number of subjects: 18
Study 17953640 — intervention group
Group type: COMPARATOR
Intervention: HAL-PDT and MAL-PDT
Number of subjects: 18
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine assays
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline Follow Back (TLFB) self-report measure
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Drug Abuse Diagnosis Scale self-report measure
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC marijuana abuse/dependence diagnostic criteria
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC cocaine abuse/dependence diagnostic criteria
Number of subjects: 190
Study 16366812 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TLFB assessments among African American participants
Number of subjects: 190
Study 12163983 — intervention group
Group type: COMPARATOR
Intervention: Mg(2+) supplementation (10 mmol for 3 days, 20 mmol for 3 days, 30 mmol for 14 days)
Number of subjects: 12
Study 12163983 — intervention group
Group type: COMPARATOR
Intervention: Mg(2+) supplementation
Number of subjects: 12
Study 9588417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABC) with 20 ml inflation volume
Number of subjects: 18
Study 9588417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABC) with 40 ml inflation volume
Number of subjects: 18
Study 9588417 — intervention group
Group type: COMPARATOR
Intervention: Control (IABC off)
Number of subjects: 18
Study 8560129 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15-30 mg/day
Number of subjects: 15
Study 8560129 — intervention group
Group type: COMPARATOR
Intervention: Placebo or behavior therapy
Number of subjects: 15
Study 2529524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel's incision
Number of subjects: 119
Study 2529524 — intervention group
Group type: COMPARATOR
Intervention: Mouchel's low transverse abdominal incision (LTA)
Number of subjects: 119
Study 320917 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine fumarate 2.68 mg
Number of subjects: 106
Study 320917 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine 4 mg
Number of subjects: 106
Study 320917 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study 31318074 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of Fvsdh gene
Number of subjects: 5
Study 31318074 — intervention group
Group type: COMPARATOR
Intervention: Control (non-transgenic strains)
Number of subjects: 5
Study 31318074 — intervention group
Group type: COMPARATOR
Intervention: Control (strain T3)
Number of subjects: 5
Study 31729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block (transtracheal and bilateral recurrent laryngeal nerve block)
Number of subjects: 30
Study 31729347 — intervention group
Group type: COMPARATOR
Intervention: Atomized lignocaine (local anesthesia atomizer)
Number of subjects: 30
Study 26988955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery stenting (PA stenting)
Number of subjects: 1183
Study 25267008 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Number of subjects: 60
Study 25267008 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22659250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-gel
Number of subjects: 32
Study 22659250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-gel + DMPA
Number of subjects: 32
Study 22659250 — intervention group
Group type: EXPERIMENTAL
Intervention: T-gel + dutasteride
Number of subjects: 32
Study 22659250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20084316 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (weekly sessions for twelve weeks)
Number of subjects: 0
Study 20084316 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 0
Study 17961301 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 50 microg
Number of subjects: 84
Study 17961301 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa 50 microg
Number of subjects: 84
Study 15381386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment (75 mg/day; 7 days)
Number of subjects: 15
Study 15381386 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 15
Study 15381386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 15
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lumbar puncture and intrathecal chemotherapy performed after 1 week of prednisolone sensitivity testing (day 8).
Number of subjects: 418
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: Good responders to prednisolone (84.5% of patients).
Number of subjects: 418
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor responders to prednisolone (15.5% of patients).
Number of subjects: 418
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse as first adverse event.
Number of subjects: 418
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding into the CSF at the time of the day 8 lumbar puncture.
Number of subjects: 418
Study 11432884 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemic blasts identified at the day 8 lumbar puncture.
Number of subjects: 418
Study 9557981 — intervention group
Group type: EXPERIMENTAL
Intervention: New automated approach for detecting SOAEs
Number of subjects: 0
Study 7983234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg nitroglycerin (NTG) sublingually
Number of subjects: 10
Study 7983234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2590601 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine 5 mg i.v.
Number of subjects: 10
Study 31741168 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fine-needle aspiration cytology (FNAC)
Number of subjects: 0
Study 31741168 — intervention group
Group type: COMPARATOR
Intervention: Watchful surveillance
Number of subjects: 0
Study 31589615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics
Number of subjects: 1000000
Study 31589615 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blockers
Number of subjects: 1000000
Study 31589615 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall healthcare seeking for LUTS
Number of subjects: 1000000
Study 27797565 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic stress reactions including PTSD and internalizing and externalizing symptoms
Number of subjects: 200
Study 27797565 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 200
Study 27797565 — intervention group
Group type: EXPERIMENTAL
Intervention: Family conflict
Number of subjects: 200
Study 25766261 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-sparing regimen
Number of subjects: 180
Study 25766261 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based therapy
Number of subjects: 180
Study 25766261 — intervention group
Group type: COMPARATOR
Intervention: Comparison of glucose-sparing regimen vs glucose-based therapy
Number of subjects: 180
Study 25766261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study 23833045 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care plus physical activity (12-week home-based programme)
Number of subjects: 200
Study 23833045 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care alone (control)
Number of subjects: 200
Study 22153779 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (30 days)
Number of subjects: 103
Study 22153779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 days)
Number of subjects: 103
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA in CRC patients (17.3 ng% ± 1.67)
Number of subjects: 200
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA for Dukes' A, B, C
Number of subjects: 200
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA in primary CRC diagnosis
Number of subjects: 200
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA in advanced disease detection
Number of subjects: 200
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA < or =5 ng%
Number of subjects: 200
Study 19579599 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal CEA above 15 ng%
Number of subjects: 200
Study 17465287 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing order (vulva first vs. thumb first)
Number of subjects: 33
Study 16422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Function Questionnaire (SFQ)
Number of subjects: 0
Study 16422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from five clinical trials and two general population surveys
Number of subjects: 0
Study 11843745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 74
Study 11843745 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 74
Study 10740421 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to sinus rhythm (SR) by means of direct current cardioversion and maintaining it
Number of subjects: 121
Study 10740421 — intervention group
Group type: COMPARATOR
Intervention: Leaving patients with atrial fibrillation (AF) treated by rate control and antithrombotic treatment
Number of subjects: 121
Study 8746907 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for 8 weeks
Number of subjects: 12
Study 1946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg)
Number of subjects: 12
Study 1946181 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg)
Number of subjects: 12
Study 7098380 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous (IV) propranolol
Number of subjects: 6
Study 7098380 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral propranolol
Number of subjects: 6
Study 7098380 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral propranolol (multiple doses every 12 h)
Number of subjects: 6
Study 7098380 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral propranolol (single dose)
Number of subjects: 6
Study 31608520 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 34
Study 31608520 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic method
Number of subjects: 34
Study 28027453 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTAP-Pethidine (treated with 1% pethidine)
Number of subjects: 79
Study 28027453 — intervention group
Group type: COMPARATOR
Intervention: OSTAP-Placebo (treated with normal saline)
Number of subjects: 79
Study 25934242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt surgery (immediate treatment group)
Number of subjects: 93
Study 25934242 — intervention group
Group type: COMPARATOR
Intervention: Postponed treatment group (surgery postponed for 3 months)
Number of subjects: 93
Study 25934242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 23280243 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 30
Study 23280243 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 30
Study 20622199 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab plus methotrexate (background therapy) every 4 weeks through week 52
Number of subjects: 302
Study 20622199 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (background therapy) every 4 weeks through week 52
Number of subjects: 302
Study 18799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assistance (TA)
Number of subjects: 240
Study 18799512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assistance (TA) in COPD patients
Number of subjects: 240
Study 18799512 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 240
Study 17986338 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry led foot care
Number of subjects: 34
Study 17986338 — intervention group
Group type: COMPARATOR
Intervention: No care (control)
Number of subjects: 34
Study 15516003 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous bone graft (n=15)
Number of subjects: 30
Study 15516003 — intervention group
Group type: COMPARATOR
Intervention: Open bone graft (n=15)
Number of subjects: 30
Study 11504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day)
Number of subjects: 30
Study 11504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg once a day)
Number of subjects: 30
Study 11504165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9766270 — intervention group
Group type: EXPERIMENTAL
Intervention: Moyamoya disease patients
Number of subjects: 9
Study 9766270 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected side
Number of subjects: 9
Study 9766270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic attack
Number of subjects: 9
Study 9766270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoperfusion
Number of subjects: 9
Study 7934974 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (continuous intravenous infusion)
Number of subjects: 19
Study 2456735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver nitrate
Number of subjects: 450
Study 2456735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracycline
Number of subjects: 450
Study 2456735 — intervention group
Group type: COMPARATOR
Intervention: Control group (forgotten babies)
Number of subjects: 450
Study 30328936 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Load (CL)
Number of subjects: 12
Study 29146648 — intervention group
Group type: EXPERIMENTAL
Intervention: E-PsEYE e-mental health intervention based on cognitive-behavioral therapy (CBT) with nine modules delivered in a stepped-care model.
Number of subjects: 174
Study 29146648 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 174
Study 26592061 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (12 weekly messages)
Number of subjects: 158